A

AbbVie

Global biopharmaceutical company developing medicines

Principal Engineer - Salesforce

Full-TimeUpdated on 10/23/2026
$124.5k - $236.5k/yr+ Long-term incentive program
Senior, Expert
Bachelor's, Master's, PhD
North Chicago, IL, USA
Hybrid
Engineering ManagementEngineering Leadership

About the job

Requirements
  • A Bachelor's degree or equivalent education with 8 years of experience, a Master's degree or equivalent education with 7 years of experience, or a PhD with 3 years of experience in application strategy, requirements, architecture, design, engineering, and related technology disciplines.
  • Experience planning, architecting, designing, developing, integrating, and operating CRM solutions on Salesforce using Service Cloud, Experience Cloud, and Health Cloud or Life Sciences Cloud; pharmaceutical or life sciences industry experience is preferred.
  • Deep hands-on experience with Salesforce CRM capabilities, including workflow automation, responsive user interfaces, data architecture, relational data modeling, data migration, data quality management, API engineering, integration design, and platform configuration.
  • In-depth knowledge of the systems development life cycle, enterprise application development practices, and technology alternatives for complex business systems.
  • Demonstrated experience leading large enterprise projects with responsibility for business requirements analysis, solution architecture, technical design, and end-to-end solution delivery; ability to lead technically complex initiatives, influence stakeholders, and guide engineering teams, architects, and vendor partners.
  • Strong understanding of enterprise architecture principles, Salesforce Well-Architected concepts, and the design of scalable, sustainable, and supportable enterprise solutions.
  • Hands-on experience with Salesforce development and configuration tools, including Apex, Triggers, Lightning Web Components, Flows, and integration features.
  • Strong background in integration architecture and engineering, including REST and SOAP APIs, middleware-based integrations, direct system-to-system interfaces, and enterprise integration patterns.
  • Ability to apply object-oriented design principles and design patterns to enterprise solutions.
  • Experience with DevOps, CI/CD/CT practices, and Salesforce ecosystem delivery tooling to support automated, repeatable, high-quality releases.
  • Ability to present complex technical concepts clearly to senior BTS leaders, business stakeholders, and cross-functional partners.
Responsibilities
  • Own the system architecture and engineering standards within the OnePRM platform, ensuring alignment with Salesforce platform architecture principles, solution architecture standards, Salesforce best practices, security requirements, validated systems expectations, and SLC governance.
  • Serve as the principal architecture and engineering leader for OnePRM, shaping solution direction, technical architecture and design, data modeling, integration strategy, engineering decisions, and platform evolution to support business growth and long-term sustainability.
  • Drive the OnePRM technical strategy and multi-year systems roadmap, including modernization, migration, consolidation, and future-state platform design in support of enterprise business priorities.
  • Evaluate emerging Salesforce capabilities, AI-enabled solutions, and engineering tools; lead proofs of concept; and translate successful pilots into scalable, production-ready capabilities that improve business value and operating efficiency.
  • Lead multiple engineering PODs and blended teams across architecture, development, QA automation, DevOps, and vendor partners, ensuring accountability for delivery commitments, quality standards, and engineering outcomes.
  • Define and govern scalable data models, workflow automation, secure integration patterns, and resilient enterprise interfaces across Salesforce and connected platforms to support reliable business operations and future growth.
  • Partner with program, product, and business leaders to execute complex release plans, manage dependencies, mitigate technical risks, and coordinate concurrent workstreams.
  • Drive CI/CD/CT modernization and shift-left quality practices, including automation, code analysis, testing rigor, and compliance controls to improve release velocity and reduce production defects.
  • Establish and govern design review, code review, release readiness, and pre-deployment approval processes to ensure consistent execution, technical quality, and compliance across internal and external delivery teams.
  • Govern technical debt, refactoring, and remediation as strategic investments that strengthen maintainability, reduce risk, and improve long-term platform scalability.
  • Maintain standards for data quality, documentation, privacy, security, and compliance in accordance with AbbVie policies, validated system requirements, and enterprise governance expectations.
  • Coach and develop application architects, tech leads, and senior engineers; strengthen technical depth across the team; and build succession capability for critical architecture and engineering roles.
  • Partner with senior business leaders, product owners, architects, and external partners to translate strategic needs into sustainable solutions and prioritize investments that maximize enterprise value.
  • Oversee team capacity, vendor performance, and budget utilization to optimize delivery efficiency, maintain accountability, and steward engineering investments responsibly.
  • Conceive, design, engineer, and implement CRM solutions that address complex business challenges and deliver measurable outcomes.
  • Lead innovation efforts, evaluate new technologies and architectural patterns, and establish engineering standards and delivery practices adopted by internal teams and strategic vendor partners.
Desired Qualifications
  • Pharmaceutical or life sciences industry experience.
  • Salesforce Administrator, Platform App Builder, Platform Developer I, Application Architect, or System Architect certification, or active pursuit of architect-level credentials.
  • Additional Salesforce Consultant certifications, such as Sales Cloud, Service Cloud, or other relevant cloud certifications.
  • Salesforce certifications in Data Architecture and Management and Integration Architecture.
  • Experience with Salesforce Data 360 and Agentforce.
  • Experience with Agentic software engineering using Agentforce Vibes.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.

Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.